Smith, A., Pivavarchyk, M., Wooters, T., Zhang, Z., Zheng, G., McIntosh, J., … Dwoskin, L. (2010). Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochemical Pharmacology, 80(3), 402-9. https://doi.org/10.1016/j.bcp.2010.03.018 (Original work published 2010)

Zhao, N., Zheng, G., Li, J., Zhao, H., Lu, C., Jiang, M., … Lu, A. (2018). Text mining of rheumatoid arthritis and diabetes mellitus to understand the mechanisms of Chinese medicine in different diseases with same treatment. Chinese Journal of Integrative Medicine. https://doi.org/10.1007/s11655-018-2825-x (Original work published 2018)

Pan, Z., Chen, M., Zhang, Q., Wang, E., Yin, L., Xu, Y., … Yuan, J. (2018). CD3-positive plasmablastic B-cell neoplasms: a diagnostic pitfall. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. https://doi.org/10.1038/modpathol.2017.177 (Original work published 2018)

Beckmann, J., Meyer, A., Pivavarchyk, M., Horton, D., Zheng, G., Smith, A., … Dwoskin, L. (2015). r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement. Neurochemical Research, 40(10), 2121-30. https://doi.org/10.1007/s11064-015-1680-4

Wilmouth, C., Zheng, G., Crooks, P., Dwoskin, L., & Bardo, M. (2013). Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats. Pharmacology, Biochemistry, and Behavior, 112, 29-33. https://doi.org/10.1016/j.pbb.2013.09.006

Meyer, A., Neugebauer, N., Zheng, G., Crooks, P., Dwoskin, L., & Bardo, M. (2013). Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo. Journal of Neurochemistry, 127(2), 187-98. https://doi.org/10.1111/jnc.12373

Dwoskin, L., Joyce, B., Zheng, G., Neugebauer, N., Manda, V., Lockman, P., … Crooks, P. (2007). Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD). Biochemical Pharmacology, 74(8), 1271-82. https://doi.org/10.1016/j.bcp.2007.07.021 (Original work published 2007)

Dwoskin, L., Pivavarchyk, M., Joyce, B., Neugebauer, N., Zheng, G., Zhang, Z., … Crooks, P. Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. Nebraska Symposium on Motivation. Nebraska Symposium on Motivation, 55, 31-63. https://doi.org/10.1007/978-0-387-78748-0_4 (Original work published 2009)

Alvers, K., Beckmann, J., Zheng, G., Crooks, P., Dwoskin, L., & Bardo, M. (2012). The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats. Psychopharmacology, 224(2), 255-62. https://doi.org/10.1007/s00213-012-2748-3

Beckmann, J., Denehy, E., Zheng, G., Crooks, P., Dwoskin, L., & Bardo, M. (2012). The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology, 220(2), 395-403. https://doi.org/10.1007/s00213-011-2488-9